Forty-six patients with refractory solid
malignancies received the new
platinum complex [2,2-bis(aminomethyl)-1,3-propanediol-N-N'] [1,1-cyclobutanedicarboxylato] [(2-)0,0')]
platinum (
zeniplatin).
Zeniplatin was given, without hydration or
mannitol, as a 60- to 90-min i.v. infusion every 3 weeks at doses ranging from 8 to 145 mg/m2. The maximum tolerated dose of
zeniplatin was 145 mg/m2. The dose-limiting toxicity of
zeniplatin was dose-related
leukopenia and
neutropenia, with the nadir usually observed between 1 and 2 weeks after
therapy and recovery usually occurring by 3 weeks after
therapy.
Thrombocytopenia was rare. The most prominent non-hematological side-effect of
zeniplatin was
nausea and
vomiting. Other non-hematological side-effects were mild or absent.
Zeniplatin did not induce significant neurological or
auditory toxicity.
Zeniplatin was not nephrotoxic at doses less than or equal to 120 mg/m2. At 145 mg/m2, the clearance decreased by a mean of 40% after 2 cycles of
therapy. Two patients, one with
malignant melanoma and one with
renal cell cancer, achieved a partial response. Pharmacokinetics of free (plasma ultrafiltrates) and total
platinum in plasma were determined in 5 patients. An in vitro study of the rate and extent of
zeniplatin binding to
protein in human plasma was also performed. Free and total
platinum were measured by flameless atomic absorption spectrometry; free
zeniplatin was measured in ultrafiltrate by HPLC. Total and free plasma
platinum concentrations were co-modelled using the information from the in vitro study.(ABSTRACT TRUNCATED AT 250 WORDS)